Refine by
Vascular Endothelial Articles & Analysis
22 news found
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...
Blockages caused by RVO reduce the oxygen supply to the retina, increasing the production of vascular endothelial growth factor (VEGF) and placental growth factor (PlGF). ...
ByBayer AG
Thus, host responses to cellular stress can influence various stages of cancer development and progression. Tumor cell-derived vascular endothelial growth factors (VEGFs) act on endothelial cells to promote angiogenesis and tumor growth, invasion, and metastasis. ...
Aflibercept 8 mg will provide a 4-fold higher molar dose compared with the standard of care (aflibercept 2 mg) with an aim to increase Vascular Endothelial Growth Factor (VEGF) suppression time. Aflibercept 8 mg was investigated in neovascular (wet) age-related macular degeneration (PULSAR) and diabetic macular edema (PHOTON) to evaluate efficacy and safety ...
ByBayer AG
” About XC001 XC001 (encoberminogene rezmadenovec) is a novel, investigational gene therapy designed to stimulate the growth of new blood vessels in the heart, in order to bypass diseased vessels and improve coronary blood flow. XC001 delivers the gene for vascular endothelial growth factor (VEGF), a naturally occurring protein, in targeted myocardial ...
Retinopathy of prematurity is a vascular disease of the immature retina of preterm babies, characterized by incomplete vessel growth which triggers elevated intraocular levels of vascular growth factor (VEGF) and abnormal vessel growth. ...
ByBayer AG
Other endpoints include mean change in central retinal thickness (CRT) and number of anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections received following administration of RGX-314. ...
“The administration of XC001 appears to have been well-tolerated at all tested doses,” said Nahush Mokadam, M.D., presenting author at AATS, Division Director, Cardiac Surgery, The Ohio State University Wexner Medical Center and Associate Director of the Heart and Vascular Center and site Principal Investigator for this study. “Objective criteria, including ...
ALYMSYS® was developed by mAbxience, a global biotech company with over a decade of experience in the development, manufacture, and commercialization of biopharmaceuticals. Bevacizumab-maly is a vascular endothelial growth factor inhibitor used in oncology. This marks the second of three biosimilars approvals Amneal expects to receive this year in oncology, ...
About FOTIVDA® (tivozanib) FOTIVDA® (tivozanib) is an oral, next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). ...
(“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs and AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company (“AVEO”) , today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate ...
Data highlighting outcomes of the subgroup of TIVO-3 patients who received tivozanib following prior axitinib therapy suggests that tivozanib, a potent and selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), is more active following prior VEGFR TKI therapy than sorafenib, a multi-targeted VEGFR TKI. ...
Treatment options for retinal diseases, such as neovascular age-related macular degeneration, diabetic retinopathy, and retinal vascular disorders, have markedly expanded following the development of anti-vascular endothelial growth factor intravitreal injection methods. ...
Low intensity shockwaves promote angiogenesis, increase nitric oxide release (NO), induces release of vascular endothelial growth factor (VEGF), stimulates reproduction of stem cells and effects tissue regeneration. ...
Henderson’s 12 grant funded research studies, his neurosurgical expertise and extensive experience overlaps many of the properties of Hemostemix stem cells, including NCP’s nerve growth factors and responses, NCP’s secretions of neurotrophin and neuroepithelial stem cell protein, and the generation of vascular endothelial growth factors,” ...
This was successfully treated with anti-vascular endothelial growth factor (VEGF) therapy. There were 16 adverse events considered to be related to the surgical procedure; the majority of these were mild (mild n=12; moderate n=4). ...
About XC001 XC001 is an investigational gene therapy designed to promote the growth of new blood vessels in the heart, with these new blood vessels bypassing diseased blood vessels and improving blood flow in the heart. XC001 deposits the gene for vascular endothelial growth factor (VEGF) in targeted heart cells. VEGF is a naturally occurring protein and it is ...
FOTIVDA is an oral, next-generation vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). ...
This was successfully treated with anti-vascular endothelial growth factor (VEGF) therapy. There were 12 adverse events considered to be related to the surgical procedure; the majority of these were mild (mild n=9; moderate n=3). ...